Burzynski Research Institute Reports Q1 2025 Losses but Sees Signs of Cost Management Progress

Burzynski Research Institute, Inc. (PINK: BZYR) has released its quarterly report for the period ending May 31, 2025. Below are key highlights and statistics from the report:

• Net Loss: The company reported a net loss of $331,451 for Q1 2025, a decrease from $371,332 in Q1 2024, representing a 10.7% improvement.
• Revenue Generation: The company has not generated significant revenue since inception, heavily relying on funding from Dr. S.R. Burzynski.
• Operating Expenses:
  • Research and Development: $270,272 in Q1 2025, up from $226,088 in Q1 2024.
  • General and Administrative: $61,179 in Q1 2025, down from $145,244 in Q1 2024.
  • Total Operating Expenses: $331,451 in Q1 2025, a decrease from $371,332 in Q1 2024.
• Cash Position: Cash and cash equivalents decreased slightly to $821 as of May 31, 2025, down from $847 as of February 28, 2025.
• Stockholder Equity: The total stockholders' equity deficit increased to $(69,716) as of May 31, 2025, from $(41,637) in the previous quarter.
• Shares Outstanding: 131,448,444 shares as of July 3, 2025.
• Funding Dependency: The company is economically dependent on continued funding from Dr. Burzynski, who has been financing operations through his medical practice.

Positive Aspects:

• Reduction in general and administrative expenses suggests improved efficiency.
• Decrease in net loss provides some indication of cost management success.

Negative Aspects:

• Continued heavy reliance on Dr. Burzynski for funding raises concerns about operational sustainability if funding ceases.
• Ongoing challenges with FDA compliance and clinical trial holds may hinder future revenue generation from drug approval.
• Increased costs in research and development due to regulatory requirements.

This quarterly report highlights Burzynski Research Institute's ongoing struggle with funding and regulatory challenges while showing signs of improved cost management in its operations.